Category: COVID 19
-
Eli Lilly’s Investigational Antibody Shows Promise as Outpatient COVID-19 Treatment
Eli Lilly has announced positive results from a phase 2 trial of its investigational antibody treatment LY-CoV555 as an outpatient treatment for mild-to-moderate COVID-19. Most patients who received a 2,800-mg dose of the antibody demonstrated near-complete viral clearance after 11 days, the company said. The trial enrolled just over 450 patients who either received a…
-
AstraZeneca Covid-19 vaccine and serious neurological symptoms
The participant who triggered a global shutdown of AstraZeneca’s Phase 3 Covid-19 vaccine trials was a woman in the United Kingdom who experienced neurological symptoms consistent with a rare but serious spinal inflammatory disorder called transverse myelitis, the drug maker’s chief executive, Pascal Soriot, said during a private conference call with investors on Wednesday morning.…
-
Sputnik-V trials results
The Lancet said the early-stage trials suggested the Sputnik-V vaccine produced a response in a component of the immune system known as T cells. Scientists have been scrutinising the role played by T cells in battling coronavirus infection, with recent findings showing these cells may provide longer-term protection than antibodies. [L1N2EH0X8] The Sputnik-V vaccine is…
-
Russia Begins 40,000 Participant Trial of COVID-19 Vaccine
Russia will begin a phase 3 trial of its Sputnik V COVID-19 vaccine on 40,000 volunteers this week, Russia’s state news agency Tass announced Friday. The controversial vaccine developed at Moscow’s Gamaleya Institute was approved for use in Russia on Aug. 11 although it had yet to enter a late-stage trial. Healthcare workers and teachers…
-
Eli Lilly Begins Phase 3 Trial of Monoclonal Antibody for COVID-19 Prevention
Eli Lilly has begun a phase 3 trial of its monoclonal antibody LY-CoV555 for prevention of COVID-19 in residents and staff at long-term care facilities in the U.S. (skilled nursing facilities, commonly referred to as nursing homes, and assisted living facilities). LY-CoV555, the lead antibody from Lilly’s collaboration with AbCellera, is a neutralizing IgG1 monoclonal antibody (mAb) against…
-
How close are we to a Coronavirus vaccine?
As per world health organization (WHO), more than 140 teams of researchers are racing to develop a safe and effective coronavirus vaccine. Vaccines normally require years of testing and additional time to produce at scale, but scientists are hoping to develop a coronavirus vaccine within 12 to 18 months. Vaccines mimic the virus – or…
-
DCGI gives permission to SII-Oxford COVID-19 vaccine for phase 2, 3 clinical trials in India
The Drugs Controller General of India (DCGI), has given its permission to Serum Institute of India (SII) to conduct the phase 2 and phase 3 human clinical trials of a coronavirus vaccine which has been developed by the University of Oxford in India. The approval for the phase 2 and 3 human clinical trial of…
-
RECOVERY trial from University of Oxford confirms benefits of dexamethasone in Covid-19
The RECOVERY (Randomised Evaluation of COVid-19 thERapY) trial led by the University of Oxford found that the use of dexamethasone resulted in lower 28-day mortality among those receiving either invasive mechanical ventilation or oxygen alone. However, there was “no clear effect” of dexamethasone for patients who were not receiving respiratory support. In the controlled, open-label trial,…
-
New study reveals Oxford coronavirus vaccine produces strong immune response
A team of scientists at Oxford University’s Jenner Institute and Oxford Vaccine Group has taken the next step towards the discovery of a safe, effective and accessible vaccine against coronavirus. The results of the Phase I/II trial published today in the scientific journal, The Lancet, indicate no early safety concerns and induces strong immune responses in…
-
Update on Covid-19 vaccine
More than four months into the coronavirus pandemic, how close are the U.S. and the world to a safe and effective vaccine? Scientists say they see steady progress and are expressing cautious optimism that a vaccine could be ready by spring. As of early July, roughly 160 vaccine projects were underway worldwide, according to the…